Participants treated with liraglutide (239), semaglutide (240), or tirzepatide (200) in the clinical trials had a percent reduction in fat mass approximately three times greater than the reduction in lean mass, leading to an overall improvement in body composition
(Thats quite rapid weight loss, if you consider that Wegovy led to 15% weight loss in a Phase 3 trial lasting over a year.) Then, at 57 days, which was four weeks after the final dose, the weight loss extended to 8.1% a finding that suggests the drug has a longer-lasting effect than currently available treatments, supporting the potential for monthly dosing
Common ICD-10-CM Codes Type 2 Diabetes E11.9 Type 2 diabetes mellitus without complications E11.65 Type 2 diabetes mellitus with hyperglycemia E11.8 Type 2 diabetes mellitus with unspecified complications Obesity / Weight Management E66.9 Obesity, unspecified E66.01 Morbid (severe) obesity due to excess calories Z68.30Z68.45 BMI codes (required by many payers) Prediabetes (often not covered for GLP-1) R73.03 Prediabetes Key Coding Tip Most payers cover GLP-1 medications only for FDA-approved indications
[10] NICE guidance for type 2 diabetes (NG28) recommends that patients maintain regular monitoring of their overall health, including urinary symptoms